PharmaShots | Incisive News in 3 Shots

Subscribe Now

NANOBIOTIX

NANOBIOTIX Signs a License Agreement with Janssen to Co-Develop and Commercialize NBTXR3

NANOBIOTIX Signs a License Agreement with Janssen to Co-Develop and Commercialize NBTXR3

July 10, 2023

Nanobiotix Initiates US Patient Enrollment of P-III Trial (NANORAY-312) for Head and Neck Cancer

Nanobiotix Initiates US Patient Enrollment of P-III Trial (NANORAY-312) for Head and Neck Cancer

December 27, 2022

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

PharmaShots Interview: Laurent Levy, CEO of Nanobiotix Shares Insights and Clinical Updates on its Nanoparticle Therapy

August 10, 2022

PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect

PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can T...

June 15, 2022

PharmaShots Weekly Snapshots (May 10 - 14, 2021)

PharmaShots Weekly Snapshots (May 10 - 14, 2021)

May 14, 2021

PharmaShots Weekly Snapshots (Jan 18 - 22, 2021)

PharmaShots Weekly Snapshots (Jan 18 - 22, 2021)

January 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us